country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Cat. No.: HY-N20751

Copy Link Print Information

Planispine A

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

CAS No.: 1202761-42-9
Formule: C₂₅H₃₀O₆
Masse moléculaire:426.50

Stockage:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (240 KB)

Planispine A Chemical Structure

CAS No.: 1202761-42-9

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Cellular Effect
- In Vitro
Chemical Information
Pureté et documentation
Calculators
Help & FAQs
Classifications
Bioz

Activité biologique

Cellular Effect

Cell Line	Type	Value	Description	References
HeLa	IC50	21.38 μM	Antiproliferative activity against human HeLa cancer cells assessed as reduction in cell viability using CellTiter 96 AQueous One Solution assay with 16 h pre-incubation of planispine A. Antiproliferative activity against human HeLa cancer cells assessed as reduction in cell viability using CellTiter 96 AQueous One Solution assay with 16 h pre-incubation of planispine A.	36364114
HeLa	IC50	3.9 μM	Antiproliferative activity against human HeLa cancer cells in combination with 25 μM cisplatin, assessed as reduction in cell viability using CellTiter 96 AQueous One Solution assay with 16 h pre-incubation of planispine A. Antiproliferative activity against human HeLa cancer cells in combination with 25 μM cisplatin, assessed as reduction in cell viability using CellTiter 96 AQueous One Solution assay with 16 h pre-incubation of planispine A.	36364114

In Vitro

Anti-cancerApoptosisCell Cycle Regulation

Anti-cancer

Planispine A (2-40 μM; 16 h) inhibits the proliferation of HeLa cells in a dose-dependent manner, with an IC₅₀ of 21.38 μM; meanwhile, this compound synergistically enhances the antiproliferative effect of Cisplatin (HY-17394). When combined with 25 μM Planispine A, the IC₅₀ of Cisplatin alone decreases to 3.9 μM^[1].
Planispine A (5-10 μM; 16 h) inhibits the Fanconi anemia pathway in HeLa cells by reducing cisplatin-induced FANCD2 foci formation and monoubiquitination modification, with monoubiquitination completely blocked at a concentration of 10 μM^[1].

Anti-cancer

Apoptosis

Planispine A (5-10 μM; 16-64 h) enhances cisplatin-induced apoptotic death of HeLa cells via a caspase-dependent mechanism, which is evidenced by increased formation of apoptotic nuclei and enhanced cleavage of caspase-3 and PARP^[1].

Anti-cancer

Cell Cycle Regulation

Combination treatment with Planispine A (3-10 μM) and cisplatin induces S-phase cell cycle arrest in HeLa cells and reduces the expression of cyclin D1^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1202761-42-9
Masse moléculaire 426.50
Formule C₂₅H₃₀O₆
SMILES

COC1=C(OC/C=C(C)/C)C=CC([C@H]2[C@@]3([H])[C@](CO2)([H])[C@@H](C4=CC(OC)=C(C=C4)O)OC3)=C1
Structure Classification
- Phenols
- Monophenols
Initial Source
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

Please store the product under the recommended conditions in the Certificate of Analysis.